Clinical trial
Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2…
NCT00491543 · Synvista Therapeutics, Inc, Industry · Completed
Key facts
| NCT number | NCT00491543 |
|---|---|
| Title | Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease |
| Lead sponsor | Synvista Therapeutics, Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes, Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | ALT-2074 |
| Enrollment | 66 |
| Start date | Jun 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Jun 26, 2007 |
| Last update posted | Jul 2, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: